CAR T-Cell Therapy Cleared Pediatric Liver Cancer
A three-year-old patient achieved a complete response after undergoing engineered cell therapy for metastatic hepatoblastoma.
Updated on Sept. 28, 2026 in Cancer
In September 2025, researchers reported that a 3-year-old child with chemotherapy-resistant metastatic hepatoblastoma maintained a complete response for one year following a novel CAR T-cell treatment. The patient had previously failed three lines of chemotherapy and surgery before enrolling in the CARE clinical trial.
Why it matters
This breakthrough provides a potential alternative for pediatric patients whose liver cancers have not responded to standard medical interventions. By engineering T cells to target specific proteins, researchers aim to overcome traditional treatment resistance.
The study recorded a complete response lasting one year following two outpatient infusions administered eight weeks apart. The CARE trial is currently tracking participants aged 1 to 21 years.
The players
CARE Clinical Trial
This is an ongoing research study evaluating the safety and efficacy of CAR T-cell therapy for patients with specific solid tumors.
The details
The therapy utilized autologous T cells engineered to target glypican-3, with IL-15 and IL-21 added to enhance antitumor activity. An inducible caspase-9 safety switch was included to mitigate potential severe toxicities, with the patient experiencing no cytokine release syndrome.
Timeline
The pediatric patient achieved a complete response lasting at least 1 year post-treatment.
Trial participants are subject to a 15-year planned follow-up period.
The Big Picture
This success follows the methodology established by the CARE clinical trial (NCT04715191). The report updates preliminary figures previously established by this ongoing research program.
This therapy offers a new treatment avenue for children with metastatic liver cancer who have exhausted conventional options. Future clinical outcomes will determine if this approach becomes a standard protocol for chemo-resistant solid tumors.
The takeaway
The use of engineered cytokines like IL-15 and IL-21 marks a significant shift in how T-cell therapies are designed to survive and act against solid tumors. Patients and families facing resistant cancers should consult with oncologists regarding eligibility for emerging cellular immunotherapy trials.
Further reading
Learn more about the latest innovations in Cancer research and patient care.
More information
Read the complete CARE trial clinical study record on the official government registry.
